https://scholars.lib.ntu.edu.tw/handle/123456789/461615
Title: | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Authors: | Liu C.-J. Chang J. Lee P.-H. Lin D.-Y. Wu C.-C. Jeng L.-B. Lin Y.-J. Mok K.-T. Lee W.-C. Yeh H.-Z. MING-CHIH HO Yang S.-S. Yang M.-D. Yu M.-C. Hu R.-H. Peng C.-Y. Lai K.-L. Chang S.S.-C. Chen P.-J. |
Issue Date: | 2014 | Publisher: | WJG Press | Journal Volume: | 20 | Journal Issue: | 32 | Start page/Pages: | 11381-11393 | Source: | World Journal of Gastroenterology | Abstract: | AIM: To demonstrate that administering heparanase inhibitor PI-88 at 160 mg/d is safe and promising in reducing hepatocellular carcinoma (HCC) recurrence for up to 3 year following curative resection. METHODS: A total of 143 patients (83.1% of the 172 participants in the phase II study) participated in the follow-up study. Of these patients, 50 had received no treatment, 48 had received 160 mg/d PI-88, and 45 had received 250 mg/d PI-88 during the phase II trial. Safety parameters and the following efficacy endpoints were investigated: (1) time to recurrence; (2) disease-free survival; and (3) overall survival. RESULTS: PI-88 at 160 mg/d delayed the onset and frequency of HCC recurrence, and provided a clinically significant survival advantage for up to 3 years after treatment compared with those of the control group: (1) the recurrence-free rate increased from 50% to 63%, and (2) time to recurrence at the 36th percentile was postponed by 78%. The efficacy of administering PI-88 at 250 mg/d was confounded by a high dropout rate (11 out of 54 patients). Additionally, subgroup analyses of patients with (1) multiple tumors or a single tumor ? 2 cm; and (2) hepatitis B or C revealed that administering PI-88 at 160 mg/d conferred the most significant survival advantage (56.8% improvement in disease-free survival, P = 0.045) for patients with both risk factors for recurrence. CONCLUSION: Administering PI-88 at 160 mg/d is a safe and well-tolerated dosage that may confer significant clinical benefits for patients with HCC. ? 2014 Baishideng Publishing Group Inc. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84909630780&doi=10.3748%2fwjg.v20.i32.11384&partnerID=40&md5=86bd6629ff4cd27bfb0096cea38a0ae9 https://scholars.lib.ntu.edu.tw/handle/123456789/461615 |
ISSN: | 1007-9327 | DOI: | 10.3748/wjg.v20.i32.11384 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.